The current stock price of NLNK is 0.89 null. In the past month the price decreased by -43.67%. In the past year, price decreased by -53.4%.
NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.
Newlink Genetics Cor
2503 SOUTH LOOP DRIVE
AMES IA 50010
CEO: Carl W. Langren
Phone: 515-296-5555
NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.
The current stock price of NLNK is 0.89 null. The price decreased by -12.75% in the last trading session.
NLNK does not pay a dividend.
NLNK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
NLNK stock is listed on the Nasdaq exchange.
ChartMill assigns a fundamental rating of 2 / 10 to NLNK. While NLNK seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months NLNK reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 28.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -4592.84% | ||
| ROA | -44.42% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |